1Sehrnitt J, Wozel G. The psoriasis area and severity index is theAdequate erlterlon to define severity in chronic plaque - type psoriasis. Dermatology,2005,210 : 194 -199.
1Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of humanized monoclonal antibody to CDlla on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42: 428-435.
2Gottlieb A, Miller B, Chaudhari U, et al.Clinical and histologic effect of subcutaneously administered anti - CDlla in patients with psoriasis. J Invest Dermatol 2000;114:840.
3Gottlieb A, Abdulghani A, Totoritis R, et al.Results of a single- dose, dose - escalating trial of anti- B7 monoclonal antibody (IDEC-114) in patients with psoriasis. J Invest Dennatol 2000; 114:546.
4Ravindra A, Nitika V. Biotherapy: a novel approach in the treatment of psoriasis. Drugs of the Fut:Lre 2002;27:1071 - 1077.
5Krueger JG, Waiters B, Miyazawa M, et al.Successful in vivo blockade of CD25 on T cells by administration of humanized anti - Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000;43:448-458.
6Asadullah K, Friedrich M, Hanneken S, et al. Effects of systemic interleukin - 10 therapy on psoriatic skin lision: histologic, immunohistologic and molecular biology findings. J Invest Dermatol 2001 ; 116:721 - 727.
7Duan H, Koga T, Kohda F, et al. Interleukin- 8 positive neutrophils in psoriasis. J Deamatol Sci 2001;26:119.
8Lohner ME, Krueger JG, Gottlieb A, et al.Clinical trals of a fully human anti - IL - 8 antibody for the treatment of psoriasis. Br J Dermatol 1999; 141:989.
9Oh CJ, Das KM, Gottlieb AB. Treatment with anti - tumor necrosis factor ( TNF - α)monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Aead Dermatol 2000;42:829 - 830.
10Kirby B, Marsland AM, Carnichael A J, et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexata. Clin Exp Dermatol 2001;26:27-29.
